RNA-Guided Genome Editing Without Bacterial RNA Processing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for genome editing in eukaryotic cells, such as ZFNs and TALENs, are inefficient and can cause toxicity, while bacterial CRISPR systems require complex RNA processing machinery.
Innovation Solution
A two-component system using RNA complementary to genomic DNA and an enzyme, like Cas9, is expressed in eukaryotic cells to bind and cleave genomic DNA in a site-specific manner, avoiding bacterial RNA processing and reducing toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If bacterial CRISPR systems are used for genome editing in eukaryotic cells, then genome editing capability is achieved, but system complexity and off-target effects increase
Solution Approach 1:
The patent extracts the essential functional components (Cas9 enzyme and guide RNA) from the complex bacterial CRISPR system, eliminating the need for bacterial RNA processing machinery while retaining genome editing capability. This simplification reduces system complexity and potential sources of error in eukaryotic cells.
Solution Approach 2:
The system is divided into two independent components: a Cas9 enzyme component and a guide RNA component. These can be separately optimized, delivered, and controlled in eukaryotic cells, allowing for simplified system architecture compared to the integrated bacterial system.
2Ease of manufacture
If bacterial CRISPR systems are used for genome editing in eukaryotic cells, then genome editing capability is achieved, but off-target effects increase
Solution Approach 1:
The patent modifies key parameters of the guide RNA including length (20-100 nucleotides), sequence composition, and structural features to optimize binding specificity in eukaryotic cells. These parameter changes enhance target discrimination and reduce off-target cleavage events while maintaining editing capability.
3Reliability
If complex bacterial RNA processing machinery is used, then CRISPR system functionality is maintained, but ease of operation in eukaryotic cells decreases
Solution Approach 1:
The patent removes the requirement for bacterial RNA processing machinery by providing guide RNA that is directly functional in eukaryotic cells. The guide RNA is designed with appropriate length and structure to function independently of bacterial processing enzymes, greatly simplifying transfection and expression in eukaryotic systems.
4Measurement precision
If guide RNA length is increased to improve specificity, then binding specificity increases, but RNA stability and delivery efficiency decrease
Solution Approach 1:
The patent identifies an optimal guide RNA length range (20-100 nucleotides, preferably 20-50 nucleotides) that balances binding specificity with RNA stability and deliverability. This parameter optimization ensures sufficient target discrimination while maintaining adequate half-life and transfection efficiency in eukaryotic cells.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables efficient and rapid homologous recombination and targeted DNA editing with minimal toxicity, allowing for precise genome modifications across multiple sites.
Implementation Method 1
The RNA hybridizes with complementary genomic DNA
Implementation Method 2
the enzyme then performs a function, such as cleavage of the genomic DNA
Data Source
AI summary
A method of altering a eukaryotic cell is provided including transfecting the eukaryotic cell with a nucleic acid encoding RNA complementary to genomic DNA of the eukaryotic cell, transfecting the eukaryotic cell with a nucleic acid encoding an enzyme that interacts with the RNA and cleaves the genomic DNA in a site specific manner, wherein the cell expresses the RNA and the enzyme, the RNA binds to complementary genomic DNA and the enzyme cleaves the genomic DNA in a site specific manner.